French biopharmaceutical company focused on drug development and commercialization in oncology, rare diseases, and neuroscience; one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
相关临床试验
289
18 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1929
进行中（未招募）
16
5.5%
已完成
205
70.9%
尚未招募
2
0.7%
招募中
18
6.2%
终止
41
14.2%
撤回
7
2.4%
暂无批准数据
- The FDA has completed its IND review period for IPN60330, the first MAIT cell engager, clearing Ipsen to begin a Phase 1 trial in the United States. - IPN60330 is a bispecific antibody built on Biomunex's BiXAb platform that engages MAIT cells and the clinically validated GPC3 tumor antigen. - The milestone triggers a payment under the November 2024 Ipsen-Biomunex global licensing deal, where Biomunex is eligible for up to $610 million plus royalties. - MAIT engagers may offer a broader therapeutic window than classical pan-T cell engagers, which activate all T cells and can cause cytokine release syndrome.
- Fulcrum Therapeutics and Slate Medicines announced a definitive all-stock merger agreement, with the combined company operating as Slate Medicines and trading on Nasdaq under the ticker "SLTE." - Slate's lead candidate SLTE-1009 is a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody designed for the preventative treatment of migraine and other headache disorders. - A concurrent oversubscribed $245 million private placement, led by Frazier Life Sciences, is expected to fund operations into 2029 and advance SLTE-1009 through Phase 1 and Phase 2 studies. - Pre-merger Fulcrum stockholders will own 5% of the combined company and receive a cash dividend estimated at $270 million, with the transaction expected to close in the fourth quarter of 2026.
- Marengo Therapeutics has nominated the first development candidate under its June 2024 TriSTAR strategic collaboration with Ipsen, marking the second TriSTAR program to enter IND-enabling development. - The TriSTAR platform employs a differentiated two-in-one mechanism combining selective Vβ T-cell activation and tumor-directed engagement to overcome limitations of traditional CD3-directed T-cell engagers. - Saso Cemerski, Ph.D., formerly Head of Discovery Immune Cell Engagement at AstraZeneca, has been appointed Senior Vice President, Head of Immunology to accelerate pipeline expansion. - Ipsen will assume responsibility for all activities following the development candidate nomination, with Marengo eligible for milestone payments under the collaboration.
- Ipsen reported H1 2026 total sales of €2.19 billion, representing 23.5% growth at constant exchange rates, and upgraded full-year 2026 sales growth guidance to greater than 20.0% at CER. - Positive Phase III results for Dysport in both episodic and chronic migraine prevention make it the first botulinum toxin to demonstrate efficacy across both indications in pivotal trials. - The Phase IIIb ELSPIRE study of Iqirvo in primary biliary cholangitis met its primary endpoint, with 85% of patients achieving ALP normalization at Week 52 versus 23% on placebo (p<0.0001). - Ipsen strengthened its pipeline through the acquisition of Memo Therapeutics AG (potravitug, a Phase II anti-BKPyV antibody) and a proposed acquisition of Kartos Therapeutics (navtemadlin, a Phase III oral MDM2 inhibitor for myelofibrosis).
- Ipsen announced that the Phase III BOLD trial evaluating Bylvay (odevixibat) versus placebo in biliary atresia patients post-Kasai hepatoportoenterostomy did not meet its primary endpoint of improved native liver survival. - The BOLD trial, the largest ever conducted in biliary atresia, enrolled 254 patients across 19 countries and generated the most comprehensive dataset assembled in this rare pediatric liver disease. - Biliary atresia remains the leading cause of pediatric liver transplantation worldwide, with no approved pharmacological treatments currently available beyond surgery. - Ipsen will conduct a comprehensive review of the full trial data before deciding on the continuation of the ongoing open-label extension study (BOLD-EXT).
- Ipsen's Dysport (abobotulinumtoxinA) met primary endpoints in both the E-BEOND and C-BEOND Phase III trials, demonstrating statistically significant reductions in monthly migraine days versus placebo. - This marks the first time a botulinum toxin has shown statistically significant efficacy in a Phase III trial for episodic migraine, positioning Dysport as a potential first-in-class preventive therapy. - The BEOND program enrolled 1,510 patients across 120 centers, with Dysport showing a safety profile consistent with its well-established use and no new safety signals. - Detailed findings will be presented at a future scientific congress, with the extension phase continuing to week 48 where all participants receive Dysport.
- Ipsen announced the acquisition of Kartos Therapeutics for $450 million upfront, with up to $1.3 billion in milestone payments, to gain navtemadlin, a Phase III oral MDM2 inhibitor for myelofibrosis. - Navtemadlin is designed as an add-on therapy to ruxolitinib for patients with suboptimal response, where median overall survival after discontinuation drops to approximately 1–2 years. - Phase Ib/II data showed 42% of ruxolitinib non-responders achieved at least a 25% spleen volume reduction at Week 24, with 71% showing a ≥20% reduction in driver variant allele frequency. - Top-line results from the pivotal Phase III POIESIS trial, enrolling over 600 patients across more than 250 sites globally, are expected in 2027, with potential regulatory submission in the 2027–2028 window.
- Ipsen has entered into a definitive agreement to acquire Memo Therapeutics in a transaction potentially exceeding €700 million, expanding its rare disease portfolio. - The acquisition centers on potravitug, a Phase II anti-BK polyomavirus antibody targeting BK polyomavirus-associated nephropathy in renal transplant patients. - Memo shareholders will receive €200 million upfront, with additional payments tied to development, regulatory approval, and sales-based milestones. - Potravitug holds FDA Fast Track designation (May 2023) and EU Orphan Drug designation (December 2025), with the deal expected to close in Q3 2026.
- Adipose tissue is now recognized as a metabolically active organ that secretes adipokines and cytokines influencing tumor initiation, progression, and therapy response. - Obesity-induced adipose tissue dysfunction is linked to increased risk and poorer outcomes in at least a dozen cancer types, though some cancers show a paradoxical benefit with immune checkpoint inhibitors. - White adipose tissue fuels tumor growth through free fatty acid mobilization, while dysregulated adipokine signaling reshapes the tumor microenvironment. - Emerging research priorities include targeting adipose–tumor communication therapeutically and integrating incretin-based therapies, exercise, and precision nutrition into cancer care.
- Biomunex Pharmaceuticals announced strategic collaborations with Gordion Bioscience and Tangramed Biotech to integrate artificial intelligence into its bispecific antibody discovery and development processes. - The partnerships aim to identify novel target combinations for cancer immunotherapy using AI-driven computational approaches and generative AI technologies. - These collaborations leverage Biomunex's proprietary BiXAb platform, which enables rapid generation of bispecific antibodies from monoclonal antibody pairs. - The company seeks to optimize target selection, shorten discovery timelines, and increase translational success probability for next-generation immunotherapies in oncology.
